MARKET

ACIU

ACIU

AC Immune
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.785
-0.065
-1.34%
After Hours: 4.785 0 0.00% 16:00 09/25 EDT
OPEN
4.950
PREV CLOSE
4.850
HIGH
4.950
LOW
4.700
VOLUME
547.36K
TURNOVER
--
52 WEEK HIGH
13.00
52 WEEK LOW
4.070
MARKET CAP
343.28M
P/E (TTM)
-13.1312
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
AC Immune's Candidate Fails in Alzheimer's Disease Study
The failure of AC Immune's (ACIU) study on Alzheimer's disease brings this challenging but promising space in focus.
Zacks · 1d ago
Mid-Afternoon Market Update: Dow Tumbles 400 Points; JinkoSolar Shares Jump
Toward the end of trading Wednesday, the Dow traded down 1.47% to 26887.20 while the NASDAQ fell 2.44% to 10,695.38. The S&P also fell, dropping 1.77% to 3,257.05.
Benzinga · 2d ago
JKS, DQ, ACB and LAC among midday movers
Gainers: JinkoSolar Holding (JKS) +18%.HireQuest (HQI) +16%.American Well (AMWL) +16%.Hilltop Holdings (HTH) +13%.Daqo New Energy (DQ) +12%.Perion Network (PERI) +12%.Qutoutiao (QTT) +11%.Entercom Communications (ETM) +10%.Aerpio Pharmaceuticals (ARPO) +9%.Annexon (ANNX) +8%.Losers: AC Immune SA (ACIU) -43%.Wave
Seekingalpha · 2d ago
Mid-Day Market Update: Gold Falls 2%; SPI Energy Shares Spike Higher
Midway through trading Wednesday, the Dow traded down 0.33% to 27197.66 while the NASDAQ fell 1.21% to 10,831.45. The S&P also fell, dropping 0.75% to 3,290.81.
Benzinga · 2d ago
American Well, MediciNova among major healthcare gainers, AC Immune, Wave Life Sciences leads losers' pack
Gainers: American Well (AMWL) +17%, MediciNova (MNOV) +13%, Mallinckrodt (MNK) +7%, Capricor Therapeutics (CAPR) +8%, Adamas Pharmaceuticals (ADMS) +6%.Losers: AC Immune (ACIU) -42%, Wave Life Sciences (WVE) -34%, Rockwell Medical (RMTI) -28%, Aurora Cannabis (ACB) -23%, NanoVibronix NAOV -15%.
Seekingalpha · 2d ago
Mid-Morning Market Update: Markets Mixed; General Mills Beats Q1 Estimates
Following the market opening Wednesday, the Dow traded up 0.18% to 27337.78 while the NASDAQ fell 0.60% to 10,898.39. The S&P also fell, dropping 0.18% to 3,309.51.
Benzinga · 2d ago
The Daily Biotech Pulse: Coronavirus Vaccine Updates From J&J & MediciNova, Australian Regulatory Nod For GW Pharma
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 22)
Benzinga · 2d ago
AC Immune Reports Top Line Results from TAURIEL Phase 2 Trial Evaluating Semorinemab in Early Alzheimers Disease
Clinical Stage Pipeline Clinical Stage Pipeline. Readout in 2020. Early-stage Pipeline Early-stage Pipeline. Key milestone in 2020.Genentech disclosed that the anti-Tau antibody did not meet the co-primary efficacy endpoint or two secondary endpoints in the TAURIEL study; the primary safety endpoint
GlobeNewswire · 2d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ACIU. Analyze the recent business situations of AC Immune through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ACIU stock price target is 12.42 with a high estimate of 17.66 and a low estimate of 8.48.
EPS
Institutional Holdings
Institutions: 66
Institutional Holdings: 21.03M
% Owned: 29.32%
Shares Outstanding: 71.74M
TypeInstitutionsShares
Increased
16
692.80K
New
17
-337.89K
Decreased
10
140.04K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.18%
Pharmaceuticals & Medical Research
+1.35%
Key Executives
Non-Executive Chairman/Independent Director
Douglas Williams
Chief Executive Officer/Co-Founder/Director/IR Contact Officer
Andrea Pfeifer
Non-Executive Vice Chairman/Independent Director
Martin Velasco
Chief Financial Officer
Joerg Hornstein
Chief Administrative Officer
Jean-Fabien Monin
Chief Scientific Officer
Marie Kosco-Vilbois
Vice President
Julien Rongere
General Counsel
Alexandre Caratsch
Other
Piergiorgio Donati
Other
Julian Gray
Other
Bojana Portmann
Other
Oliver Sol
Non-Executive Independent Director
Peter Bollmann
Non-Executive Independent Director
Thomas Graney
Non-Executive Independent Director
Werner Lanthaler
Non-Executive Independent Director
Roy Twyman
Non-Executive Independent Director
Friedrich von Bohlen und Halbach
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ACIU
AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The Company's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. It has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of AC Immune SA stock information, including NASDAQ:ACIU real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACIU stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ACIU stock methods without spending real money on the virtual paper trading platform.